Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.
The primary aim of this study was to show a 10% reduction in prostate cancer mortality. The final analysis (median follow-up of 11 years) showed about an 11% reduction in prostate cancer-specific mortality.
Fosså believes that the benefit actually was even greater, as elderly men die of other causes which cannot be affected by treatment. Fosså says there are plans to analyze how many patients died of cardiovascular disease. This is an important question to answer as castration treatment can increase the risk of cardiovascular disease.
<<< View more from the 2014 GU Cancers Symposium